RPG Life Sciences Share Price Target 2026 Analyst Forecast Bull and Bear Case

RPG Life Sciences (NSE: RPGLIFE) is a Pharmaceutical Formulations and Healthcare company trading at Rs 2,294 with a market capitalisation of Rs 3,792 crore. Analysts have set the RPG Life Sciences share price target at Rs 2,750 for 2026, based on FY27 earnings projections and sector re-rating potential. This article covers the complete 2026 price forecast including sector tailwinds, key risks, and bull and bear scenarios.

Click Here – Get Free Investment Predictions

RPG Life Sciences Share Price Target 2026: Key Takeaways

• RPG Life Sciences share price target 2026: Rs 2,750 (20% upside from CMP Rs 2,294)
• Bull case: Rs 3,350 | Bear case: Rs 1,850
• Ticker: RPGLIFE | Sector: Pharmaceutical Formulations and Healthcare | MCap: Rs 3,792 crore
• 52W range: Rs 1,733 to Rs 2,725 | PE: 22x
• Key catalyst: Q4 FY26 results and FY27 earnings confirmation in 2026
• Key risk: FY27 earnings miss or FII outflows from Indian equities

RPG Life Sciences Company Overview

RPG Life Sciences (NSE: RPGLIFE) is a Mumbai-based RPG Group pharmaceutical company manufacturing anti-infective, immunosuppressant, and psychiatry branded formulations for India and international markets. At CMP Rs 2,294 against a 52 week range of Rs 1,733 to Rs 2,725, the stock trades at a meaningful discount to its 52 week high. Market capitalisation is Rs 3,792 crore with trailing PE of 22x. Compared to peers in pharma like Ajanta Pharma and Unichem Laboratories, RPG Life Sciences is positioned as a potential re-rating candidate toward the Rs 2,750 price objective on FY27 earnings delivery.

Parameter	Value
NSE Ticker	RPGLIFE
Sector	Pharmaceutical Formulations and Healthcare
CMP (2026)	Rs 2,294
52 Week High	Rs 2,725
52 Week Low	Rs 1,733
Market Cap	Rs 3,792 crore
Trailing PE	22x
12-Month Analyst Target	Rs 2,750
Bull Case Target	Rs 3,350
Bear Case Target	Rs 1,850

Why Is the RPG Life Sciences Share Price Target Set at Rs 2,750 for 2026

FY27 Earnings Recovery and Revenue Acceleration

The RPG Life Sciences share price target of Rs 2,750 rests on analyst projections of 15 to 20 percent PAT growth in FY27. Q4 FY26 results released in 2026 confirming the earnings trajectory are the most direct catalyst for re-rating from CMP Rs 2,294.

Structural Sector Tailwinds in Pharmaceutical Formulations and Healthcare

The Pharmaceutical Formulations and Healthcare sector is expanding on the back of India’s domestic demand growth, PLI scheme support, and rising corporate investment. RPG Life Sciences’s position among peers in pharma like Ajanta Pharma and Unichem Laboratories creates a structural growth runway, with sustained outperformance being one of the key conditions for the Rs 3,350 bull case to materialise.

RBI Rate Cut Cycle and Lower Cost of Capital

India’s RBI rate cut cycle in 2026 is reducing borrowing costs and stimulating end market demand. Lower interest costs improve RPG Life Sciences’s EPS trajectory, narrowing the gap between current earnings and the FY27 estimates that underpin the Rs 2,750 analyst consensus.

Union Budget 2026-27 Capex Push and Policy Support

Budget 2026-27’s Rs 11.21 lakh crore infrastructure capex and PLI scheme continuity create a favourable backdrop for RPG Life Sciences’s Pharmaceutical Formulations and Healthcare operations, improving the probability of achieving the Rs 2,750 price objective through FY27 earnings delivery.

FII Flow Normalisation After the 2026 Tariff Shock

As global macro conditions normalise through 2026, FII flows into quality Indian equities are gradually recovering. At 22x PE, RPG Life Sciences is positioned as a beneficiary of institutional reallocation toward the Rs 3,350 bull case over the medium term.

RPG Life Sciences Share Price Targets: Short Term, 12 Month, and Long Term

Short Term RPG Life Sciences Share Price Target

Near-term support for RPG Life Sciences is anchored close to the 52 week low of Rs 1,733. A confirmed Q4 FY26 earnings recovery in 2026 is the trigger for an initial 10 to 15 percent re-rating from CMP Rs 2,294.

12-Month RPG Life Sciences Share Price Target 2026

The 12-month RPG Life Sciences share price target 2026 is Rs 2,750, implying approximately 20 percent upside from CMP Rs 2,294. This base case assumes in-line FY27 earnings delivery and partial normalisation of FII flows.

Long Term RPG Life Sciences Share Price Target: FY27 to FY28

The long term RPG Life Sciences share price target for FY27 to FY28 is Rs 3,350 in the bull case, requiring full earnings delivery, re-rating among peers in pharma like Ajanta Pharma and Unichem Laboratories, and sustained institutional buying over a 2 to 3 year horizon.

Bull Case and Bear Case Scenarios for RPG Life Sciences in 2026

Bull Case RPG Life Sciences Share Price Target: Rs 3,350

The bull case RPG Life Sciences share price target of Rs 3,350 materialises when FY27 earnings beat analyst estimates, Pharmaceutical Formulations and Healthcare tailwinds accelerate, and FII flows return strongly to Indian equities, representing approximately 45 percent potential upside from CMP Rs 2,294.

Bear Case RPG Life Sciences Share Price Target: Rs 1,850

The bear case RPG Life Sciences share price target of Rs 1,850 materialises if FY27 earnings disappoint or FII outflows depress the broader market, risking a test of support near the 52 week low of Rs 1,733.

Scenario	Target	Key Conditions
Bull Case	Rs 3,350	FY27 beat, sector re-rating, FII inflows
Base Case (Analyst Target)	Rs 2,750	In-line FY27 delivery, partial FII recovery
Bear Case	Rs 1,850	FY27 miss, guidance cut, FII outflows persist

Key Risks That Could Derail the RPG Life Sciences 2026 Price Objective

Global Macro and US Tariff Headwinds

Prolonged tariff tensions and global demand slowdown remain prominent macro risks to the RPG Life Sciences share price target of Rs 2,750, with FII outflows being the direct transmission mechanism to Indian equity valuations.

FY27 Earnings Miss and Guidance Risk

An FY27 earnings miss or downward guidance revision would compress valuation multiples and is the most direct company-specific risk to the Rs 2,750 analyst price objective. Investors must monitor quarterly results and management commentary closely.

Competitive Intensity Among Pharmaceutical Formulations and Healthcare Peers

Intensifying competition from peers in pharma like Ajanta Pharma and Unichem Laboratories could compress RPG Life Sciences’s market share and pricing power, a structural risk that must be weighed when assessing the defensibility of the earnings trajectory underpinning the Rs 2,750 analyst target for 2026.

Liquidity Risk and FII Selling Pressure

Sustained FII outflows from Indian equities can delay the re-rating process regardless of company-level improvement. Investors should maintain position sizing discipline and stop losses to protect capital.

How to Invest in RPG Life Sciences

Check the Univest Screener for live data

Before considering any investment based on the RPG Life Sciences share price target of Rs 2,750, review Q4 FY26 results and FY27 guidance released in 2026. Focus on revenue growth, margin trends, and management commentary on Pharmaceutical Formulations and Healthcare sector demand.

Open a Demat account with a SEBI registered stockbroker to trade RPG Life Sciences (NSE: RPGLIFE) with full regulatory protection. Study the competitive landscape among peers in pharma like Ajanta Pharma and Unichem Laboratories before executing any position.

Plan your entry using the 52 week low of Rs 1,733 as a key support reference. A confirmed FY27 earnings uptick validates the entry case for the Rs 2,750 price objective. Always set a stop loss below the 52 week low.

Restrict any single stock to 3 to 5 percent of your total equity portfolio. Always consult a SEBI registered financial advisor before investing. SEBI Registration No. INH000013776.

Download the Univest iOS App or the Univest Android App to track RPG Life Sciences’s live share price and receive daily stock recommendations.

FAQs on RPG Life Sciences Share Price Target 2026

What is the RPG Life Sciences share price target for 2026?

Ans. The RPG Life Sciences share price target 2026 is Rs 2,750, implying approximately 20 percent upside from CMP Rs 2,294. Bull case is Rs 3,350, bear case is Rs 1,850.

What was the RPG Life Sciences share price target for 2025?

Ans. The 2025 price objective for RPG Life Sciences was based on FY26 earnings projections. The current 2026 analyst consensus is Rs 2,750, reflecting FY27 growth potential from CMP Rs 2,294.

Is RPG Life Sciences a good investment at Rs 2,294?

Ans. At Rs 2,294, RPG Life Sciences offers potential upside toward Rs 2,750 if FY27 earnings recover. Whether this represents a good entry depends on individual risk tolerance. Consult a SEBI registered financial advisor before investing.

What are the key risks to the RPG Life Sciences share price target 2026?

Ans. Key risks to the RPG Life Sciences share price target of Rs 2,750 include FY27 earnings miss, global tariff headwinds, FII outflows, and competitive pressure in Pharmaceutical Formulations and Healthcare. Monitoring quarterly results is essential.

What is the 52 week high and low of RPG Life Sciences?

Ans. The 52 week high of RPG Life Sciences is Rs 2,725 and the 52 week low is Rs 1,733. At CMP Rs 2,294, the stock offers potential upside toward the Rs 2,750 price objective.

What are the main growth catalysts for RPG Life Sciences in 2026?

Ans. Key catalysts include FY27 PAT recovery, Pharmaceutical Formulations and Healthcare tailwinds, RBI rate cuts in 2026, Budget 2026-27 policy support, and normalisation of FII flows into Indian equities.

How does RPG Life Sciences compare to its peers?

Ans. RPG Life Sciences operates in Pharmaceutical Formulations and Healthcare alongside peers in pharma like Ajanta Pharma and Unichem Laboratories. At CMP Rs 2,294 with MCap Rs 3,792 crore, it is a potential re-rating candidate toward the RPG Life Sciences share price target of Rs 2,750 on FY27 delivery.

What is the RPG Life Sciences share price target for 2027?

Ans. The long-term RPG Life Sciences share price target for FY27 to FY28 is Rs 3,350 in the bull case, assuming earnings growth, sector re-rating, and FII inflows. Consult a SEBI registered financial advisor for personalised guidance.